{"transactions":[{"id":706816,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-17T20:14:39.000Z","date":"2026-07-16","kind":"grant","planned":false,"acquired":true,"shares":64643,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to 50% of the options on July 16, 2027, the first anniversary of the grant date, and as to the remaining 50% of the options on July 16, 2028, the second anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates."}],"balance_after":64643,"derivative":{"exercise_price":3.2,"expiration_date":"2036-07-16","underlying":"Common Stock","underlying_shares":64643},"source":{"system":"sec-edgar","filing":"0001612095-26-000002","document":"wk-form4_1784319276.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000161209526000002/wk-form4_1784319276.xml","form_type":"4"}},{"id":921808,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-03T21:33:56.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":50900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable as to 25% of the options on February 2, 2027, the first anniversary of the grant date, with the remaining options vesting in monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates."}],"balance_after":50900,"derivative":{"exercise_price":8.1,"expiration_date":"2036-02-02","underlying":"Common Stock","underlying_shares":50900},"source":{"system":"sec-edgar","filing":"0001601485-26-000002","document":"wk-form4_1770154430.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000160148526000002/wk-form4_1770154430.xml","form_type":"4"}},{"id":921807,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2026-02-03T21:33:56.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":25400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") that will vest as to 25% of the RSUs on February 2, 2027, the first anniversary of the grant date, with the remaining RSUs vesting in annual installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Each RSU represents the right to receive one share of common stock, par value $0.01 per share, of the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\") that will vest as to 25% of the RSUs on February 2, 2027, the first anniversary of the grant date, with the remaining RSUs vesting in annual installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Each RSU represents the right to receive one share of common stock, par value $0.01 per share, of the Issuer."}],"balance_after":57381,"source":{"system":"sec-edgar","filing":"0001601485-26-000002","document":"wk-form4_1770154430.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000160148526000002/wk-form4_1770154430.xml","form_type":"4"}},{"id":1284763,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-04T21:10:33.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to 25% of the options on the first anniversary of the grant date (February 3, 2026), with the remaining options vesting in equal monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates."}],"balance_after":44000,"derivative":{"exercise_price":8.92,"expiration_date":"2035-02-03","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001601485-25-000014","document":"wk-form4_1738703424.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000160148525000014/wk-form4_1738703424.xml","form_type":"4"}},{"id":1394410,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-02T20:12:12.000Z","date":"2024-09-30","kind":"grant","planned":false,"acquired":true,"shares":28200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fifty percent (50%) of the stock options vest on September 30, 2025, the one-year anniversary of the grant date, with the remaining fifty percent (50%) of the stock options to vest on September 30, 2026, the two-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date."}],"balance_after":28200,"derivative":{"exercise_price":5.03,"expiration_date":"2024-09-30","underlying":"Common Stock","underlying_shares":28200},"source":{"system":"sec-edgar","filing":"0001601485-24-000049","document":"wk-form4_1727899926.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000160148524000049/wk-form4_1727899926.xml","form_type":"4"}},{"id":1658814,"issuer":{"id":299,"kind":"organization","name":"Elicio Therapeutics, Inc.","symbol":"ELTX"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"officer":true,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-05T11:01:41.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":28200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty five percent (25%) of the stock options vest on February 1, 2025, the one-year anniversary of the grant date, with the remaining options vesting in monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates."}],"balance_after":28200,"derivative":{"exercise_price":4.5,"expiration_date":"2034-02-01","underlying":"Common Stock","underlying_shares":28200},"source":{"system":"sec-edgar","filing":"0001140361-24-005497","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000114036124005497/form4.xml","form_type":"4"}},{"id":2603683,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Director"}}],"security":"Class B Ordinary Shares","published_at":"2021-08-13T23:38:40.000Z","date":"2021-08-11","kind":"disposition_to_issuer","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On April 15, 2021, Consonance-HFW Acquisition Corp. (the \"Issuer\") entered into a Business Combination Agreement (the \"Business Combination Agreement\"), by and among the Issuer, Perseverance Merger Sub Inc. (\"Merger Sub\"), and Surrozen, Inc. (\"Surrozen\").  The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021.  Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the \"Domestication\") and, in connection with the Domestication, (A) the Issuer's name changed to \"Surrozen, Inc.\","},{"field":"security","element":"securityTitle","label":"F2","text":"(Continued from Footnote 1) (B) each outstanding Class A Ordinary Share of the Issuer (\"Class A Share\") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the \"Common Stock\") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), pursuant to Rule 16b-7 under the Exchange Act, and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the \"Merger\").  The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the \"Business Combination\"."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On April 15, 2021, Consonance-HFW Acquisition Corp. (the \"Issuer\") entered into a Business Combination Agreement (the \"Business Combination Agreement\"), by and among the Issuer, Perseverance Merger Sub Inc. (\"Merger Sub\"), and Surrozen, Inc. (\"Surrozen\").  The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021.  Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the \"Domestication\") and, in connection with the Domestication, (A) the Issuer's name changed to \"Surrozen, Inc.\","},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"(Continued from Footnote 1) (B) each outstanding Class A Ordinary Share of the Issuer (\"Class A Share\") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the \"Common Stock\") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), pursuant to Rule 16b-7 under the Exchange Act, and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the \"Merger\").  The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the \"Business Combination\"."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On April 15, 2021, Consonance-HFW Acquisition Corp. (the \"Issuer\") entered into a Business Combination Agreement (the \"Business Combination Agreement\"), by and among the Issuer, Perseverance Merger Sub Inc. (\"Merger Sub\"), and Surrozen, Inc. (\"Surrozen\").  The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021.  Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the \"Domestication\") and, in connection with the Domestication, (A) the Issuer's name changed to \"Surrozen, Inc.\","},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"(Continued from Footnote 1) (B) each outstanding Class A Ordinary Share of the Issuer (\"Class A Share\") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the \"Common Stock\") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), pursuant to Rule 16b-7 under the Exchange Act, and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the \"Merger\").  The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the \"Business Combination\"."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On April 15, 2021, Consonance-HFW Acquisition Corp. (the \"Issuer\") entered into a Business Combination Agreement (the \"Business Combination Agreement\"), by and among the Issuer, Perseverance Merger Sub Inc. (\"Merger Sub\"), and Surrozen, Inc. (\"Surrozen\").  The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021.  Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the \"Domestication\") and, in connection with the Domestication, (A) the Issuer's name changed to \"Surrozen, Inc.\","},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"(Continued from Footnote 1) (B) each outstanding Class A Ordinary Share of the Issuer (\"Class A Share\") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the \"Common Stock\") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), pursuant to Rule 16b-7 under the Exchange Act, and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the \"Merger\").  The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the \"Business Combination\"."}],"balance_after":0,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-21-033040","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000089924321033040/doc4.xml","form_type":"4"}},{"id":2603682,"issuer":{"id":6092,"kind":"organization","name":"Surrozen, Inc./DE"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former Director"}}],"security":"Common Stock","published_at":"2021-08-13T23:38:40.000Z","date":"2021-08-11","kind":"grant","acquired":true,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On April 15, 2021, Consonance-HFW Acquisition Corp. (the \"Issuer\") entered into a Business Combination Agreement (the \"Business Combination Agreement\"), by and among the Issuer, Perseverance Merger Sub Inc. (\"Merger Sub\"), and Surrozen, Inc. (\"Surrozen\").  The Business Combination (as defined below) pursuant to the Business Combination Agreement closed on August 11, 2021.  Pursuant to the terms of the Business Combination Agreement, on the closing date: (i) the Issuer became a Delaware corporation (the \"Domestication\") and, in connection with the Domestication, (A) the Issuer's name changed to \"Surrozen, Inc.\","},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) (B) each outstanding Class A Ordinary Share of the Issuer (\"Class A Share\") and each outstanding Class B Ordinary Share of the Issuer became one share of common stock of Issuer (the \"Common Stock\") in transactions exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), pursuant to Rule 16b-7 under the Exchange Act, and (C) each outstanding warrant of the Issuer became one warrant to purchase one share of Common Stock; and (ii) following the Domestication, Merger Sub merged with and into Surrozen, with Surrozen as the surviving company in the merger and, after giving effect to such merger, continuing as a wholly-owned subsidiary of Issuer (the \"Merger\").  The Domestication, the Merger and the other transactions contemplated by the Business Combination Agreement are hereinafter referred to as the \"Business Combination\"."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0000899243-21-033040","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000089924321033040/doc4.xml","form_type":"4"}},{"id":3649945,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2019-02-19T22:08:22.000Z","date":"2019-02-15","kind":"sale","acquired":false,"shares":775,"price":39.59,"value":30682.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.33 to $39.695. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":271943,"source":{"system":"sec-edgar","filing":"0001209191-19-011187","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919119011187/doc4.xml","form_type":"4"}},{"id":3665916,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2019-02-12T00:10:23.000Z","date":"2019-02-11","kind":"sale","acquired":false,"shares":13975,"price":38.55,"value":538736.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.27 to $38.55. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":272718,"source":{"system":"sec-edgar","filing":"0001209191-19-009116","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919119009116/doc4.xml","form_type":"4"}},{"id":3668166,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-02-08T21:28:15.000Z","date":"2019-02-06","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"1/48th of the shares subject to the stock option vest and become exercisable each month following February 6, 2019, subject to the reporting person's continuous service."}],"balance_after":30000,"derivative":{"exercise_price":38.47,"expiration_date":"2029-02-05","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-19-008526","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919119008526/doc4.xml","form_type":"4"}},{"id":3668165,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2019-02-08T21:28:15.000Z","date":"2019-02-06","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries of the grant date, subject to the reporting person's continuous service."}],"balance_after":286693,"source":{"system":"sec-edgar","filing":"0001209191-19-008526","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919119008526/doc4.xml","form_type":"4"}},{"id":3668164,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2019-02-08T21:28:15.000Z","date":"2019-02-06","kind":"tax_withholding","acquired":false,"shares":1512,"price":38.47,"value":58166.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"Shares withheld to cover tax obligation from settlement of vested restricted stock units."}],"balance_after":271693,"source":{"system":"sec-edgar","filing":"0001209191-19-008526","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919119008526/doc4.xml","form_type":"4"}},{"id":3668163,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2019-02-08T21:28:15.000Z","date":"2019-02-06","kind":"sale","acquired":false,"shares":9698,"price":38.78,"value":376088.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.67 to $38.89. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":273205,"source":{"system":"sec-edgar","filing":"0001209191-19-008526","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919119008526/doc4.xml","form_type":"4"}},{"id":3668162,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2019-02-08T21:28:15.000Z","date":"2019-02-06","kind":"sale","acquired":false,"shares":2677,"price":38.04,"value":101833.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $37.61 to $38.54. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":282903,"source":{"system":"sec-edgar","filing":"0001209191-19-008526","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919119008526/doc4.xml","form_type":"4"}},{"id":3763221,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2018-11-15T21:53:37.000Z","date":"2018-11-15","kind":"sale","acquired":false,"shares":775,"price":33.81,"value":26202.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $33.65 to $34.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":285580,"source":{"system":"sec-edgar","filing":"0001209191-18-058763","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919118058763/doc4.xml","form_type":"4"}},{"id":3806574,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2018-09-27T20:56:25.000Z","date":"2018-09-26","kind":"sale","acquired":false,"shares":13500,"price":43.08,"value":581580.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $42.70 to $43.525. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":286355,"source":{"system":"sec-edgar","filing":"0001209191-18-052465","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919118052465/doc4.xml","form_type":"4"}},{"id":3808320,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2018-09-25T21:02:28.000Z","date":"2018-09-25","kind":"sale","acquired":false,"shares":3500,"price":41.23,"value":144305.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $41.10 to $41.475. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":299855,"source":{"system":"sec-edgar","filing":"0001209191-18-052162","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919118052162/doc4.xml","form_type":"4"}},{"id":3808319,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2018-09-25T21:02:28.000Z","date":"2018-09-25","kind":"sale","acquired":false,"shares":10000,"price":40.26,"value":402600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.975 to $40.95. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":303355,"source":{"system":"sec-edgar","filing":"0001209191-18-052162","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919118052162/doc4.xml","form_type":"4"}},{"id":3808318,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2018-09-25T21:02:28.000Z","date":"2018-09-24","kind":"sale","acquired":false,"shares":3931,"price":40.53,"value":159323.43,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.20 to $40.70. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":313355,"source":{"system":"sec-edgar","filing":"0001209191-18-052162","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919118052162/doc4.xml","form_type":"4"}},{"id":3808317,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2018-09-25T21:02:28.000Z","date":"2018-09-24","kind":"sale","acquired":false,"shares":14069,"price":39.74,"value":559102.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.15 to $40.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":317286,"source":{"system":"sec-edgar","filing":"0001209191-18-052162","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919118052162/doc4.xml","form_type":"4"}},{"id":3841824,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2018-08-16T21:12:09.000Z","date":"2018-08-15","kind":"sale","acquired":false,"shares":775,"price":37.54,"value":29093.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $37.20 to $37.80. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":331355,"source":{"system":"sec-edgar","filing":"0001209191-18-047107","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919118047107/doc4.xml","form_type":"4"}},{"id":3930865,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-05-17T00:37:01.000Z","date":"2018-05-15","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"1/48th of the shares subject to the stock option vest and become exercisable each month following October 15, 2014."}],"balance_after":25000,"derivative":{"exercise_price":11,"expiration_date":"2021-10-15","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-18-030722","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919118030722/doc4.xml","form_type":"4"}},{"id":3930864,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2018-05-17T00:37:01.000Z","date":"2018-05-15","kind":"sale","acquired":false,"shares":9252,"price":46.02,"value":425777.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $45.85 to $46.30. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":332130,"source":{"system":"sec-edgar","filing":"0001209191-18-030722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919118030722/doc4.xml","form_type":"4"}},{"id":3930863,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2018-05-17T00:37:01.000Z","date":"2018-05-15","kind":"sale","acquired":false,"shares":9638,"price":45.21,"value":435733.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $44.80 to $45.80. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":341382,"source":{"system":"sec-edgar","filing":"0001209191-18-030722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919118030722/doc4.xml","form_type":"4"}},{"id":3930862,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2018-05-17T00:37:01.000Z","date":"2018-05-15","kind":"sale","acquired":false,"shares":6885,"price":44.44,"value":305969.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $43.75 to $44.75. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":351020,"source":{"system":"sec-edgar","filing":"0001209191-18-030722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919118030722/doc4.xml","form_type":"4"}},{"id":3930861,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2018-05-17T00:37:01.000Z","date":"2018-05-15","kind":"exercise","acquired":true,"shares":25000,"price":11,"value":275000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."}],"balance_after":357905,"source":{"system":"sec-edgar","filing":"0001209191-18-030722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919118030722/doc4.xml","form_type":"4"}},{"id":3981950,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2018-03-27T20:16:39.000Z","date":"2018-03-26","kind":"sale","acquired":false,"shares":1100,"price":40.29,"value":44319.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.20 to $40.50. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":332905,"source":{"system":"sec-edgar","filing":"0001209191-18-021728","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919118021728/doc4.xml","form_type":"4"}},{"id":3981949,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2018-03-27T20:16:39.000Z","date":"2018-03-26","kind":"sale","acquired":false,"shares":17227,"price":39.76,"value":684945.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted January 25, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $39.15 to $40.15. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":334005,"source":{"system":"sec-edgar","filing":"0001209191-18-021728","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919118021728/doc4.xml","form_type":"4"}},{"id":4047716,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Restricted Stock Units","published_at":"2018-02-21T01:24:32.000Z","date":"2018-02-15","kind":"exercise","acquired":false,"shares":553,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Fully vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The earlier of (i) January 10, 2021 or (ii) the recipient's termination date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":553},"source":{"system":"sec-edgar","filing":"0001209191-18-011670","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919118011670/doc4.xml","form_type":"4"}},{"id":4047715,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2018-02-21T01:24:32.000Z","date":"2018-02-15","kind":"exercise","acquired":true,"shares":553,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units (\"RSUs\")."}],"balance_after":351232,"source":{"system":"sec-edgar","filing":"0001209191-18-011670","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919118011670/doc4.xml","form_type":"4"}},{"id":4066213,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2018-02-13T01:55:57.000Z","date":"2018-02-09","kind":"tax_withholding","acquired":false,"shares":4925,"price":41.7,"value":205372.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares withheld to cover tax obligation from settlement of vested restricted stock units."}],"balance_after":350679,"source":{"system":"sec-edgar","filing":"0001209191-18-009408","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919118009408/doc4.xml","form_type":"4"}},{"id":4070454,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-02-08T22:46:04.000Z","date":"2018-02-06","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to the stock option vest and become exercisable each month following February 6, 2018."}],"balance_after":35000,"derivative":{"exercise_price":35.8,"expiration_date":"2025-02-06","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001209191-18-008513","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919118008513/doc4.xml","form_type":"4"}},{"id":4070453,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2018-02-08T22:46:04.000Z","date":"2018-02-06","kind":"tax_withholding","acquired":false,"shares":4426,"price":35.8,"value":158450.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares withheld to cover tax obligation from settlement of vested restricted stock units."}],"balance_after":355604,"source":{"system":"sec-edgar","filing":"0001209191-18-008513","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919118008513/doc4.xml","form_type":"4"}},{"id":4070452,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2018-02-08T22:46:04.000Z","date":"2018-02-06","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries of the grant date, subject to the reporting person's continuous service."}],"balance_after":360030,"source":{"system":"sec-edgar","filing":"0001209191-18-008513","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919118008513/doc4.xml","form_type":"4"}},{"id":4158226,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Restricted Stock Units","published_at":"2017-11-17T23:27:14.000Z","date":"2017-11-15","kind":"exercise","acquired":false,"shares":829,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in\norder for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015.  The service-based vesting condition provides that 1/48th of the total number of shares shall vest monthly from January 10, 2014, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The earlier of (i) January 10, 2021 or (ii) the recipient's termination date."}],"balance_after":553,"derivative":{"underlying":"Common Stock","underlying_shares":829},"source":{"system":"sec-edgar","filing":"0001209191-17-061608","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919117061608/doc4.xml","form_type":"4"}},{"id":4158225,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2017-11-17T23:27:14.000Z","date":"2017-11-15","kind":"sale","acquired":false,"shares":1604,"price":13.36,"value":21429.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 27, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $13.25 to $13.55. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":342530,"source":{"system":"sec-edgar","filing":"0001209191-17-061608","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919117061608/doc4.xml","form_type":"4"}},{"id":4158224,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2017-11-17T23:27:14.000Z","date":"2017-11-15","kind":"exercise","acquired":true,"shares":829,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units (\"RSUs\")."}],"balance_after":344134,"source":{"system":"sec-edgar","filing":"0001209191-17-061608","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919117061608/doc4.xml","form_type":"4"}},{"id":4184903,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2017-10-17T20:46:56.000Z","date":"2017-10-16","kind":"sale","acquired":false,"shares":6000,"price":14.35,"value":86100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 27, 2016."}],"balance_after":343305,"source":{"system":"sec-edgar","filing":"0001209191-17-057159","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919117057159/doc4.xml","form_type":"4"}},{"id":4207222,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2017-09-18T21:46:46.000Z","date":"2017-09-15","kind":"sale","acquired":false,"shares":6000,"price":15.3,"value":91800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 27, 2016."}],"balance_after":349305,"source":{"system":"sec-edgar","filing":"0001209191-17-053206","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919117053206/doc4.xml","form_type":"4"}},{"id":4230768,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Restricted Stock Units","published_at":"2017-08-17T21:35:49.000Z","date":"2017-08-15","kind":"exercise","acquired":false,"shares":829,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in\norder for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015.  The service-based vesting condition provides that 1/48th of the total number of shares shall vest monthly from January 10, 2014, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The earlier of (i) January 10, 2021 or (ii) the recipient's termination date."}],"balance_after":1382,"derivative":{"underlying":"Common Stock","underlying_shares":829},"source":{"system":"sec-edgar","filing":"0001209191-17-049448","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919117049448/doc4.xml","form_type":"4"}},{"id":4230767,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2017-08-17T21:35:49.000Z","date":"2017-08-15","kind":"sale","acquired":false,"shares":7604,"price":14.75,"value":112159.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 27, 2016."}],"balance_after":355305,"source":{"system":"sec-edgar","filing":"0001209191-17-049448","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919117049448/doc4.xml","form_type":"4"}},{"id":4230766,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2017-08-17T21:35:49.000Z","date":"2017-08-15","kind":"exercise","acquired":true,"shares":829,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units (\"RSUs\")."}],"balance_after":362909,"source":{"system":"sec-edgar","filing":"0001209191-17-049448","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919117049448/doc4.xml","form_type":"4"}},{"id":4255307,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2017-07-18T20:24:26.000Z","date":"2017-07-17","kind":"sale","acquired":false,"shares":6000,"price":14.92,"value":89520.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 27, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.9161 to $14.95. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":362080,"source":{"system":"sec-edgar","filing":"0001209191-17-045509","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919117045509/doc4.xml","form_type":"4"}},{"id":4279152,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2017-06-16T20:47:48.000Z","date":"2017-06-15","kind":"sale","acquired":false,"shares":6000,"price":12.65,"value":75900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 27, 2016."}],"balance_after":368080,"source":{"system":"sec-edgar","filing":"0001209191-17-040561","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919117040561/doc4.xml","form_type":"4"}},{"id":4315832,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Restricted Stock Units","published_at":"2017-05-17T20:58:39.000Z","date":"2017-05-15","kind":"exercise","acquired":false,"shares":829,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in\norder for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015.  The service-based vesting condition provides that 1/48th of the total number of shares shall vest monthly from January 10, 2014, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The earlier of (i) January 10, 2021 or (ii) the recipient's termination date."}],"balance_after":2211,"derivative":{"underlying":"Common Stock","underlying_shares":829},"source":{"system":"sec-edgar","filing":"0001209191-17-033195","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919117033195/doc4.xml","form_type":"4"}},{"id":4315831,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2017-05-17T20:58:39.000Z","date":"2017-05-15","kind":"sale","acquired":false,"shares":7604,"price":14.99,"value":113983.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction pursuant to Rule 10b5-1 Plan adopted December 7, 2015."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.65 to $15.20. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":374080,"source":{"system":"sec-edgar","filing":"0001209191-17-033195","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919117033195/doc4.xml","form_type":"4"}},{"id":4315830,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2017-05-17T20:58:39.000Z","date":"2017-05-15","kind":"exercise","acquired":true,"shares":829,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units (\"RSUs\")."}],"balance_after":381684,"source":{"system":"sec-edgar","filing":"0001209191-17-033195","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919117033195/doc4.xml","form_type":"4"}},{"id":4349763,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2017-04-19T20:29:09.000Z","date":"2017-04-17","kind":"sale","acquired":false,"shares":6000,"price":17.28,"value":103680.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 27, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $17.00 to $17.55. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":380855,"source":{"system":"sec-edgar","filing":"0001209191-17-027470","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919117027470/doc4.xml","form_type":"4"}},{"id":4380068,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2017-03-17T21:07:57.000Z","date":"2017-03-15","kind":"sale","acquired":false,"shares":6000,"price":19.6,"value":117600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted December 7, 2015."}],"balance_after":386855,"source":{"system":"sec-edgar","filing":"0001209191-17-021452","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919117021452/doc4.xml","form_type":"4"}},{"id":4442664,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Restricted Stock Units","published_at":"2017-02-17T01:08:59.000Z","date":"2017-02-15","kind":"exercise","acquired":false,"shares":829,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in\norder for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015.  The service-based vesting condition provides that 1/48th of the total number of shares shall vest monthly from January 10, 2014, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The earlier of (i) January 10, 2021 or (ii) the recipient's termination date."}],"balance_after":3040,"derivative":{"underlying":"Common Stock","underlying_shares":829},"source":{"system":"sec-edgar","filing":"0001209191-17-011764","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919117011764/doc4.xml","form_type":"4"}},{"id":4442663,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2017-02-17T01:08:59.000Z","date":"2017-02-15","kind":"sale","acquired":false,"shares":7604,"price":15.49,"value":117785.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction pursuant to Rule 10b5-1 Plan adopted December 7, 2015."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.30 to $15.70. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":392855,"source":{"system":"sec-edgar","filing":"0001209191-17-011764","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919117011764/doc4.xml","form_type":"4"}},{"id":4442662,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2017-02-17T01:08:59.000Z","date":"2017-02-15","kind":"exercise","acquired":true,"shares":829,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units (\"RSUs\")."}],"balance_after":400459,"source":{"system":"sec-edgar","filing":"0001209191-17-011764","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919117011764/doc4.xml","form_type":"4"}},{"id":4457222,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2017-02-10T23:23:06.000Z","date":"2017-02-09","kind":"sale","acquired":false,"shares":13975,"price":15.46,"value":216053.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 27, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $15.15 to $15.90. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":399630,"source":{"system":"sec-edgar","filing":"0001209191-17-009718","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919117009718/doc4.xml","form_type":"4"}},{"id":4461605,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2017-02-08T22:37:47.000Z","date":"2017-02-06","kind":"grant","acquired":true,"shares":49500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries of the grant date, subject to the reporting person's continuous service."}],"balance_after":413605,"source":{"system":"sec-edgar","filing":"0001209191-17-008830","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919117008830/doc4.xml","form_type":"4"}},{"id":4488207,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, R&D & Chief Scientific Of"}}],"security":"Common Stock","published_at":"2017-01-19T00:52:05.000Z","date":"2017-01-17","kind":"sale","acquired":false,"shares":6000,"price":14.27,"value":85620.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 27, 2016."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $14.00 to $14.55. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":364105,"source":{"system":"sec-edgar","filing":"0001209191-17-004333","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919117004333/doc4.xml","form_type":"4"}},{"id":4520620,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2016-12-16T00:28:56.000Z","date":"2016-12-15","kind":"sale","acquired":false,"shares":6000,"price":15.4,"value":92400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 27, 2016."}],"balance_after":370105,"source":{"system":"sec-edgar","filing":"0001209191-16-155509","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919116155509/doc4.xml","form_type":"4"}},{"id":4545056,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2016-11-22T23:40:49.000Z","date":"2016-11-21","kind":"sale","acquired":false,"shares":7068,"price":17.85,"value":126163.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted September 27, 2016."}],"balance_after":376105,"source":{"system":"sec-edgar","filing":"0001209191-16-151797","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919116151797/doc4.xml","form_type":"4"}},{"id":4550570,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted Stock Units","published_at":"2016-11-17T21:53:11.000Z","date":"2016-11-15","kind":"exercise","acquired":false,"shares":829,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock or a cash settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs were granted with both (a) a liquidity event-based vesting condition and (b) a service-based vesting condition, both of which conditions must be satisfied in\norder for the RSUs to vest. The liquidity event-based condition was satisfied upon the closing of the Issuer's initial public offering (the \"IPO\"). The shares that vested on the closing date of the IPO, and the shares that vested thereafter through May 15, 2015, were settled on May 15, 2015.  The service-based vesting condition provides that 1/48th of the total number of shares shall vest monthly from January 10, 2014, subject to the holder's continuous service through each such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The earlier of (i) January 10, 2021 or (ii) the recipient's termination date."}],"balance_after":3869,"derivative":{"underlying":"Common Stock","underlying_shares":829},"source":{"system":"sec-edgar","filing":"0001209191-16-150914","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919116150914/doc4.xml","form_type":"4"}},{"id":4550569,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2016-11-17T21:53:11.000Z","date":"2016-11-15","kind":"sale","acquired":false,"shares":1604,"price":19.95,"value":31999.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Transaction pursuant to Rule 10b5-1 Plan adopted December 7, 2015."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in Column 4 is a weighted average sale price. The prices actually received ranged from $19.55 to $20.30. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range."}],"balance_after":383173,"source":{"system":"sec-edgar","filing":"0001209191-16-150914","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919116150914/doc4.xml","form_type":"4"}},{"id":4550568,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2016-11-17T21:53:11.000Z","date":"2016-11-15","kind":"exercise","acquired":true,"shares":829,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of vested restricted stock units (\"RSUs\")."}],"balance_after":384777,"source":{"system":"sec-edgar","filing":"0001209191-16-150914","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919116150914/doc4.xml","form_type":"4"}},{"id":4596258,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":29759,"kind":"person","name":"Haqq Christopher","position":1,"cik":"0001612095","reported_name":"Haqq Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2016-09-23T23:26:35.000Z","date":"2016-09-22","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units vest over 4 years, 50% on the 2nd anniversary of the grant date of September 22, 2016 and 25% on the anniversary of the grant date of September 22, 2016 in each of the following years."}],"balance_after":383948,"source":{"system":"sec-edgar","filing":"0001209191-16-142708","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1612095/000120919116142708/doc4.xml","form_type":"4"}}]}